<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-8T17AEQZ/f7613a20-d3e4-4730-9dd7-c0bb9f767bcc/HTML"><dcterms:extent>24 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-8T17AEQZ/b30c4b9e-8bf5-4e8e-977b-2c4749ce0ee9/PDF"><dcterms:extent>77 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-8T17AEQZ/40641665-032c-4213-9aa3-acc8de39d129/TEXT"><dcterms:extent>19 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-8T17AEQZ"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2010</dcterms:issued><dc:creator>Ojsteršek, Zvezdana</dc:creator><dc:creator>Tepeš, Bojan</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:79</dc:format><dc:format xml:lang="sl">str. 19-24</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:26667993</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-8T17AEQZ</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">antimikrobno zdravljenje</dc:subject><dc:subject xml:lang="en">Clarithromycin</dc:subject><dc:subject xml:lang="en">Cross-Sectional Studies</dc:subject><dc:subject xml:lang="en">Diagnostic Use</dc:subject><dc:subject xml:lang="en">Drug Therapy</dc:subject><dc:subject xml:lang="en">Duodenal Ulcer</dc:subject><dc:subject xml:lang="sl">Duodenalni ulkus</dc:subject><dc:subject xml:lang="en">Gastritis</dc:subject><dc:subject xml:lang="en">Helicobacter Infections</dc:subject><dc:subject xml:lang="en">Helicobacter Pylori</dc:subject><dc:subject xml:lang="en">Helicobacter, infekcije</dc:subject><dc:subject xml:lang="sl">Klaritromicin</dc:subject><dc:subject xml:lang="sl">Metronidazol</dc:subject><dc:subject xml:lang="en">Metronidazole</dc:subject><dc:subject xml:lang="sl">Omeprazol</dc:subject><dc:subject xml:lang="en">Omeprazole</dc:subject><dc:subject xml:lang="sl">Presečne študije</dc:subject><dc:subject xml:lang="en">Stomach Ulcer</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">Treatment Outcome</dc:subject><dc:subject xml:lang="en">Urea</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dc:subject xml:lang="sl">Zdravljenje, izid</dc:subject><dc:subject xml:lang="sl">Želodčni ulkus</dc:subject><dc:subject xml:lang="sl">želodec</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Uspešnost zdravljenja okužbe z bakterijo Helicobacter pylori v Sloveniji v letu 2008| Cumulative Helicobacter pylori eradication rates in Slovenia in the year 2008|</dc:title><dc:description xml:lang="sl">Background: The aim of the study was to examine cumulative Helicobacter pylorieradication rates in Slovenia in the year 2008 that can be achieved in clinical practice by clasic first and second regimens suggested by Maastricht recommendations and third line empirical regimens. Methods: We performed crosssectional study that included 500 consecutive patients, who underwent urea breath test aft er Helicobacter pylori eradication regimens in AM DC Rogaška in the period from January to September 2008.We analysed eradication rates after OMC regimen, 7 days (omeprazole, metronidazole, clarithromycin), OAC regimen, 7 days (omeprazole, amoxicillin, clarithromycin), BMTO regimen, 14 days (colloid bismuth subcitrate, metronidazole, oxytetracycline, omeprazole) and OA regimen, 14 days (omeprazole, amoxicillin). Results: Total 308 patients received OMC regimen with eradication rate 78.6 % (95 % CI 76.3%-80.9%). Total 80 patients received OAC regimen with eradication rate 80% (95 % CI 75.6 %-84.4 %). After failure of the first regimen, they receivedthe opposite first-line regimen. In the case of eradication failure, 23 patients received BMTO regimen as a third-line therapy with eradication rate 82.6 % and 14 patients received OA regimen with eradication rate 64.3 %. Nine of 388 patients who started Helicobacter pylori eradication treatment in our study remained positive aft er they received all the available therapeutical regimens (2,3 %). Conclusions. Cumulative Helicobacter pylori eradication rate in Slovenia in the year 2008 is still very high-97.7 %. Theseresults are comparable with the results in other European countries</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-8T17AEQZ"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-8T17AEQZ" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-8T17AEQZ/b30c4b9e-8bf5-4e8e-977b-2c4749ce0ee9/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-8T17AEQZ/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-8T17AEQZ" /></ore:Aggregation></rdf:RDF>